Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival

Albain, 2008, Adding a new agent to the old in metastatic breast cancer: progress, promise, and challenges, Discussion presented at 2008 American Society of Clinical Oncology Annual Meeting

Mayfield, 2007, Progression-free survival: patient benefit or lower standard, Life Raft Group

Allison, 2008, Trouble at the office [abstract 23], Nat Biotechnol, 26, 967, 10.1038/nbt0908-967

Chakravarty, 2008, Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues, Stat Methods Med Res., 17, 515, 10.1177/0962280207081862

Panageas, 2007, When you look matters: the effect of assessment schedule on progression-free survival, J Natl Cancer Inst, 99, 428, 10.1093/jnci/djk091

Sherrill, 2008, Disease progression as a predictor of overall survival in metastatic breast cancer: a meta-analysis [abstract 564], Eur J Cancer, 6, 216, 10.1016/S1359-6349(08)70880-2

Burzykowski, 2008, Exploring and validating surrogate endpoints in colorectal cancer, Lifetime Data Anal, 14, 54, 10.1007/s10985-007-9079-4

Hackshaw, 2005, Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer, Br J Cancer, 93, 1215, 10.1038/sj.bjc.6602858

Buyse, 2007, Progression-free survival is a surrogate for survival in advanced colorectal cancer, J Clin Oncol, 25, 5218, 10.1200/JCO.2007.11.8836

Tang, 2007, Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy, J Clin Oncol, 25, 4562, 10.1200/JCO.2006.08.1935

R Development Core Team, 2006, R: A Language and Environment for Statistical Computing

Bowater, 2008, The relationship between progression-free and post-progression survival in treating four types of metastatic cancer, Cancer Lett., 262, 48, 10.1016/j.canlet.2007.11.032

Berry, 2008, Discussion of “Prediction of survival benefits from progression-free survival in patients with advanced non-small cell cancer: evidence from a pooled analysis of 2,838 patients randomized in 7 trials,” by Marc E. Buyse

Burzykowski, 2008, Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer, J Clin Oncol, 26, 1987, 10.1200/JCO.2007.10.8407

Buyse, 2008, Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: evidence from a pooled analysis of 2,838 patients randomized in 7 trials, J Clin Oncol, 26, 8019, 10.1200/jco.2008.26.15_suppl.8019